Submitted by: Alkermes
Posted: May 07, 2020 – 11:30 AM EST
In 2018, we significantly enhanced CaRE™, our proprietary risk mitigation program designed to encourage employees to preemptively identify and address EHSS risks and enhance sustainability.
CaRE has been rolled out across the organization to engage leaders and colleagues from various parts of our business to take an active role in building a preventive and sustainable EHSS risk-focused culture. The program includes a number of components that help encourage high employee engagement and contribute to our low incident rates, including:
Workplace “walkthroughs” by cross-functional leaders to improve risk awareness and encourage proactive action, fostering open and honest discussions with employees;
Our “Good Save” system to help identify and resolve workplace hazards and risks;
Improved data collection and management to support risk mitigation and measurement efforts; and
Recognition for those employees engaged in CaRE efforts, to amplify and encourage our collective goal of continuous improvement.
Read more in the 2019 Corpororate Responsibility Report
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
For more information, please contact:There is currently no contact information.